Investigations
Mega-CHOEP phase III is a randomised study comparing conventional chemoimmunotherapy with R-CHOEP-14 with high-dose chemotherapy plus Rituximab with autologous stem cell transplantation in high-risk patients aged 61 to 80 years with Aggressive Non-Hodgkin’s Lymphoma.
RICOVER-60 is a randomised study comparing 6 and 8 cycles of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD20 antibody Rituximab in patients aged 61 to 80 years with Aggressive Non-Hodgkin’s Lymphoma.
Submitter: René Hänsel
Studies: RICOVER-60
Resources: RICOVER-60 trial data, RICOVER-60 trial metadata
Demographics, reference pathology diagnosis, Outcome (Event-free survival, Progression-free survival, Overall survival)
Submitter: René Hänsel
Studies: SEXIE-R-CHOP-14
Resources: SEXIE-R-CHOP-14 metadata, SEXIE-R-CHOP-14 trial data
Submitter: René Hänsel
Studies: SMARTE-R-CHOP-14
Resources: SMARTE-R-CHOP-14 metadata, SMARTE-R-CHOP-14 trial data
Submitter: René Hänsel
Studies: RICOVER-noRTh
Resources: RICOVER-noRTh metadata, RICOVER-noRTh trial data
